Blumberg, Friedrich C. and Riegger, Guenter A. J. and Pfeifer, Michael (2002) Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. CHEST, 121 (5). pp. 1566-1571. ISSN 0012-3692
Full text not available from this repository. (Request a copy)Abstract
Study objectives: Aerosolized iloprost, a stable prostacyclin analog, improves functional capacity even in patients with pulmonary hypertension who did not show a vigorous hemodynamic response after iloprost inhalation at rest. We therefore speculated that aerosolized iloprost elicits more beneficial effects on pulmonary hemodynamics during exercise than at rest. Design and setting: A prospective, open, uncontrolled study at a university hospital. Patients: Sixteen patients with primary or secondary pulmonary hypertension. Interventions: Bight-heart catheterization at rest and during exercise before and after the inhalation iloprost, 14 to 28 mug. Results: Before iloprost treatment, exercise increased mean (+/- SD) pulmonary artery pressure (PAPm) from 45 +/- 8 to 70 +/- 13 mm Hg, cardiac output from 3.7 +/- 1.0 to 5.8 +/- 2.4 L/min, and pulmonary vascular resistance (PVR) from 904 +/- 322 to 1,013 +/- 432 dyne.s.em 5 (each p < 0.05). After recovery, iloprost reduced PAPm from 44 8 to 41 +/- 6 mm Hg, increased cardiac output from 3.7 +/- 1.0 to 4.9 +/- 1.4 L/min, and lowered PVR from 902 +/- 350 to 636 +/- 248 dyne.s.cm(-5) (each p < 0.05). During exercise after iloprost, PAPm increased to 57 +/- 8 mm Hg, cardiac output to 7.0 +/- 3.0 L/min, and PVR to 673 +/- 279 dyne.s.cm(-5) (each p < 0.05 vs first exercise test). Systemic BP was not altered significantly by iloprost treatment during exercise. Conclusions: Aerosolized iloprost treatment exerts more favorable effects on pulmonary hemodynamics during exercise than at rest. These findings explain the functional improvement observed in patients with pulmonary hypertension who show only a moderate pulmonary vasodilatory response during iloprost inhalation at rest. Whether these beneficial effects have prognostic significance needs to be elucidated by further study.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EPOPROSTENOL PROSTACYCLIN; SECONDARY; NIFEDIPINE; SURVIVAL; THERAPY; DISEASE; exercise test; hypertension; prostaglandins; pulmonary |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Oct 2021 04:24 |
| Last Modified: | 27 Oct 2021 04:24 |
| URI: | https://pred.uni-regensburg.de/id/eprint/40293 |
Actions (login required)
 |
View Item |
